PSMA PET/CT accurately detects recurrent prostate cancer in 67-year-old man. 18F-DCFPyL-PSMA PET/CT shows extensive, intensely PSMA-avid local recurrence in prostate (bottom row; solid arrow) in ...

Patient undergoing PET/CT Investigators zero in on which patients might benefit most from PSMA-PET-guided salvage radiation therapy for post-RP recurrent prostate cancer. Study findings presented at ...

Standardized criteria in PSMA PET/CT for patient selection for 177 Lu-PSMA radionuclide therapy (RNT) have been established, but further refinement to enhance therapeutic responses is warranted.

NORTH BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., a global leader ...

The study published by Bastiaan M Privé and colleagues in The Lancet Oncology represents, to our knowledge, the first randomised phase 2 trial evaluating lutetium-177–PSMA-617 (177Lu-PSMA-617) in ...

Prostate-specific membrane antigen (PSMA) is a protein found in small amounts in your prostate gland. When you have prostate cancer, you have many times more PSMA than normal. This makes PSMA a good ...

A novel targeted radionuclide therapy has shown promising clinical activity and low toxicity in a group of heavily pretreated men with metastatic castration-resistant prostate cancer (mCRPC). The ...

The novel radiopharmaceutical 18F-PSMA-1007 is both effective and readily available for detecting malignant prostate cancer lesions, according to research published in the April issue of The Journal ...

New prostate cancer research shows that adding an interim scan during therapy can help guide a patient's treatment. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging ...

The researchers also assessed a prognostic biomarker, fluorodeoxyglucose (FDG) PET. A high volume of disease on FDG-PET (metabolic tumor volume [MTV] > 200 mL) was associated with a worse prognosis ...